SCHEMBL10036075

SCHEMBL10036075

CCN1C(=O)/C(=C2/Oc3ccccc3N2CC)SC1=S

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 16/20 0.57
▸ KMT2A Q03164 16/20 0.57
▸ MAPT P10636 12/20 0.55
▸ MAPK1 P28482 6/20 0.55
▸ TDP1 Q9NUW8 5/20 0.55
▸ NPSR1 Q6W5P4 4/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ ALDH1A1 P00352 6/20 0.52
▸ HTT P42858 2/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ MMP14 P50281 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ LMNA P02545 3/20 0.48
▸ THRB P10828 1/20 0.48
▸ POLB P06746 3/20 0.47
▸ TSHR P16473 3/20 0.47
▸ MMP13 P45452 2/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10623018 1.00 MEN1 (0.57) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL10623015 1.00 MEN1 (0.57) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL11881513 0.92 MEN1 (0.64) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL11881517 0.92 MEN1 (0.64) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL13531851 0.90 MEN1 (0.48) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL13531849 0.88 MEN1 (0.49) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL14220089 0.87 MEN1 (0.45) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL5688044 0.87 MAPT (0.46) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL5688049 0.87 MAPT (0.46) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL13397638 0.87 MEN1 (0.52) MEN1KMT2AMAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback